Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of physician-diagnosed ragweed- and grass pollen-induced rhinitis with or without conjunctivitis of \>1 year duration, with or without asthma~* Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Randomization Visits and must agree to remain abstinent or use (or have their partner use) any one of the acceptable methods of birth control within the projected duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraception.~Exclusion Criteria:~* Unstable, uncontrolled or severe asthma treated with long-acting beta agonists (LABAs) at the time of Screening~* Received immunosuppressive treatment within 3 months prior to Randomization (except steroids for allergic reactions other than asthma)~* History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen~* Diagnosis of eosinophilic esophagitis~* History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy~* Female and breastfeeding, pregnant or intending to become pregnant~* Received another form of allergen immunotherapy with the past month~* Previously exposed to MK-3641 (RAGWITEK®) or other sublingual ragweed immunotherapy~* Previously exposed to MK-7243 (GRASTEK®) or other sublingual grass immunotherapy~* Known history of allergy, hypersensitivity, or intolerance to the excipient ingredients of the study drug (except for Ambrosia artemisiifolia and/or Phleum pratense), or self-injectable epinephrine~* Unable to or will not comply with the use of self-injectable epinephrine~* Used an investigational drug within 30 days prior to Screening Visit, or plans to participate in another interventional clinical trial during the duration of this trial~* Family member of the investigational or sponsor staff involved in this trial~* Participating in this same trial at another investigational site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-3641+ MK-7243 (Type: EXPERIMENTAL): Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.

Based on this trial design, predict the completion outcome and termination type (if applicable).